Meeting
2018 ASCO Annual Meeting
A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].
Authors
Stephen K. L. Chia
British Columbia Cancer Agency, Vancouver, BC, Canada
Stephen K. L. Chia , Philippe L. Bedard , John Hilton , Eitan Amir , Karen A. Gelmon , Rachel Anne Goodwin , Diego Villa , Michael Cabanero , Heather Ritter , Dongsheng Tu , Ming Sound Tsao , Lesley Seymour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT02649686
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1029)
DOI
10.1200/JCO.2018.36.15_suppl.1029
Abstract #
1029
Poster Bd #
110
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Elevated serum activin A and PD-L1 and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line HER2+ metastatic breast cancer.
First Author: Prashanth Reddy Moku
Poster
2018 ASCO Annual Meeting
Serum PD-L1 and outcomes in CCTG MA.31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer patients (trastuzumab arm only).
First Author: Kim Leitzel
Poster
2023 ASCO Annual Meeting
Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC).
First Author: Hyo S. Han
Poster
2017 ASCO Annual Meeting
First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).
First Author: Maria Alsina